Clinical Trials Browser

Phase 2 × Gastric Adenocarcinoma × Bevacizumab × Clear all

NCT06667050 2024-10-31

CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Gastric Adenocarcinoma